Velagliflozin
Clinical data
Trade namesSenvelgo
License data
Routes of
administration		By mouth
ATCvet code
Legal status
Legal status
Identifiers
  • 2-[(4-cyclopropylphenyl)methyl]-4-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H25NO5
Molar mass395.455 g·mol−1
3D model (JSmol)
  • C1CC1C2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C#N
  • InChI=1S/C23H25NO5/c24-11-17-8-7-16(23-22(28)21(27)20(26)19(12-25)29-23)10-18(17)9-13-1-3-14(4-2-13)15-5-6-15/h1-4,7-8,10,15,19-23,25-28H,5-6,9,12H2/t19-,20-,21+,22-,23+/m1/s1
  • Key:SENUNDCNOYAWGN-ZQGJOIPISA-N
  • Key:UWKBFNWQMSGEPG-ZHNCTCHCSA-N

Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats.[1][2] Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.[3] It is taken by mouth.[1]

Medical uses

Velagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin.[1][2][3]

References

  1. 1 2 3 4 "Senvelgo- velagliflozin solution". DailyMed. 8 November 2023. Retrieved 13 December 2023.
  2. 1 2 https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14320 Public Domain This article incorporates text from this source, which is in the public domain.
  3. 1 2 "Dear Veterinarian Letter regarding important safety conditions associated with the use of Senvelgo (velagliflozin oral solution) for improving glycemic control in certain cats with diabetes mellitus". U.S. Food and Drug Administration. 4 December 2023. Retrieved 13 December 2023. Public Domain This article incorporates text from this source, which is in the public domain.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.